Author

Robert Willingson

University of Cape Town; Francis Crick Institute; Imperial College London - Cited by 40,448

Biography

Robert Willingson is affiliated to Tuberculosis Laboratory, Francis Crick Institute, UK. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.  His research interests reflect in his wide range of publications in various national and international journals.   
Title
Cited by
Year
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
R Keeton, MB Tincho, A Ngomti, R Baguma, N Benede, A Suzuki, K Khan, ...Nature 603 (7901), 488-492, 2022202
387
2022
Outcomes of laboratory‐confirmed SARS‐CoV‐2 infection in the Omicron‐driven fourth wave compared with previous waves in the Western Cape Province, South Africa
MA Davies, R Kassanjee, P Rousseau, E Morden, L Johnson, W Solomon, ...Tropical Medicine & International Health 27 (6), 564-573, 2022202
114
2022
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
TM Walker, P Miotto, CU Köser, PW Fowler, J Knaggs, Z Iqbal, M Hunt, ...The Lancet Microbe 3 (4), e265-e273, 2022202
71
2022
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
A Fendler, STC Shepherd, L Au, KA Wilkinson, M Wu, AM Schmitt, Z Tippu, ...Cancer cell 40 (2), 114-116, 2022202
57
2022
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province …
MA Davies, E Morden, P Rousseau, J Arendse, JL Bam, L Boloko, ...International Journal of Infectious Diseases 127, 63-68, 2023202
47
2023
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis
CRyPTIC ConsortiumEuropean Respiratory Journal 60 (4), 2022202
35
2022
Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish …
H Hussey, MA Davies, A Heekes, C Williamson, Z Valley-Omar, D Hardie, ...International Journal of Infectious Diseases 118, 150-154, 202
22
2022
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics
CRyPTIC ConsortiumPLoS biology 20 (8), e3001721, 2022202
19
2022
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
K van den Berg, TN Glatt, M Vermeulen, F Little, R Swanevelder, C Barrett, ...Scientific reports 12 (1), 2552, 2022202
16
2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
A Fendler, STC Shepherd, L Au, M Wu, R Harvey, KA Wilkinson, ...Cell Reports Medicine 3 (), 0781, 2022202
10
2022
GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection
EP Amaral, TW Foreman, S Namasivayam, KL Hilligan, KD Kauffman, ...Journal of Experimental Medicine 21 (11), e20220504, 2022202
9
2022
Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker …
L Boloko, C Schutz, N Sibiya, A Balfour, A Ward, M Shey, MP Nicol, ...The Lancet Microbe 3 (), e521-e532, 2022202
7
2022
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
SB Georghiou, TC Rodwell, A Korobitsyn, SH Abbadi, K Ajbani, ...European Respiratory Journal 59 (4), 2022202
7
2022
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated …
AG Davis, S Wasserman, C Stek, M Maxebengula, C Jason Liang, ...Clinical Infectious Diseases 6 (8), 1412-1422, 2023202
7
2023
Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation study
Baseline IL- is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation studyAN Gupte, P Kumar, M Araújo-Pereira, V Kulkarni, M Paradkar, ...European Respiratory Journal 59 (4), 2022202
6
2022
Prevalence and Determinants of Vitamin D Deficiency in 1825 Cape Town Primary Schoolchildren: A Cross-Sectional Study
Prevalence and Determinants of Vitamin D Deficiency in 182 Cape Town Primary Schoolchildren: A Cross-Sectional StudyK Middelkoop, N Walker, J Stewart, C Delport, DA Jolliffe, J Nuttall, ...Nutrients 14 (6), 1263, 2022202
5
2022
Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa
E Du Bruyn, C Stek, R Daroowala, Q Said-Hartley, M Hsiao, G Schafer, ...Nature Communications 14 (1), 188, 2023202
5
2023
A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth …
PW Fowler, C Wright, H Spiers, T Zhu, EML Baeten, SW Hoosdally, ...Elife 11, e7046, 2022202
5
2022
Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders
C Morfill, S Pankratova, P Machado, NK Fernando, A Regoutz, ...ACS applied materials & interfaces 1 (2), 75-760, 2022202
4
2022
Cognitive Impairment in Tuberculous Meningitis
AG Davis, AJ Dreyer, C Albertyn, M Maxebengula, C Stek, S Wasserman, ...Clinical Infectious Diseases 76 (5), 82-89, 2023202
4
2023

Referred From: https://scholar.google.co.za/citations?user=SqwGUN0AAAAJ&hl=en

Cited by
Citations 40448
h-index 97
i10-index 335
Recommended Journals
Open Access Journals